Analyst Price Target is $3.33
▲ +223.62% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for LAVA Therapeutics in the last 3 months. The average price target is $3.33, with a high forecast of $6.00 and a low forecast of $2.00. The average price target represents a 223.62% upside from the last price of $1.03.
Current Consensus is
Hold
The current consensus among 5 investment analysts is to hold stock in LAVA Therapeutics. This rating changed within the last month from a Buy consensus rating.
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
Read More
